Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUFYLLIN vs AMINOPHYLLINE DYE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
FDA-approved: Relief and prevention of bronchospasm associated with asthma, chronic bronchitis, and emphysema.,Off-label: Apnea of prematurity, COPD exacerbations.
Treatment of bronchospasm associated with asthma, chronic bronchitis, emphysema, and COPD,Apnea of prematurity (off-label)
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Dyphylline is not metabolized by the liver; it is primarily excreted unchanged by the kidneys. Approximately 80% is eliminated unchanged in urine.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4, CYP2E1, and CYP2D6. Metabolism may be saturated, leading to nonlinear kinetics at therapeutic doses.
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Approximately 40-50% bound to plasma proteins, primarily albumin.
Approximately 40% bound, primarily to albumin. In neonates, protein binding is lower (about 30%).
0.5-0.7 L/kg. This indicates distribution into total body water with some tissue binding.
Approximately 0.5 L/kg (range 0.3-0.7 L/kg). Higher in premature infants and neonates (0.6-0.9 L/kg). Vd corresponds to total body water; aminophylline distributes into extracellular and intracellular fluid.
Oral immediate-release: 90-100%. Rectal: approximately 80-90%. Sustained-release: 70-90% with delayed absorption.
Oral immediate-release: nearly 100%. Oral sustained-release: 80-100% depending on formulation. Rectal: variable (80-100%). Intravenous: 100%.
Cr Cl 30-50 m L/min: administer 50-75% of normal dose. Cr Cl <30 m L/min: administer 25-50% of normal dose. Consider monitoring theophylline levels.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 50% and monitor serum theophylline levels closely.
Child-Pugh A: no adjustment. Child-Pugh B: administer 50% of normal dose. Child-Pugh C: avoid use or administer 25% of normal dose with close monitoring.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: use alternative therapy or reduce dose by 80-90% with close monitoring.
Children <1 year: 100-200 mg/day in 3-4 divided doses. Children 1-9 years: 200-300 mg/day in 3-4 divided doses. Children 9-16 years: 200-400 mg/day in 3-4 divided doses. Weight-based alternative: 10-20 mg/kg/day in 3-4 divided doses.
Loading dose: 5-6 mg/kg IV over 30 minutes. Maintenance IV infusion: age 1-6 months: 0.5 mg/kg/hour; 6-12 months: 0.6-0.7 mg/kg/hour; 1-9 years: 0.8-1.0 mg/kg/hour; >9 years: 0.5-0.7 mg/kg/hour. Oral: 5-6 mg/kg every 6 hours (immediate-release) or every 12 hours (extended-release).
Initiate at lower end of dosing range (200 mg 3 times daily). Monitor theophylline levels and adjust dose to maintain trough concentration of 5-15 mcg/m L. Reduce dose if concurrent medications affecting hepatic metabolism.
Lower initial doses recommended (e.g., 300-400 mg/day oral) with slower titration, as clearance is decreased. Monitor serum theophylline levels and adjust to achieve 5-15 mcg/m L.
No FDA black box warning.
Theophylline has a narrow therapeutic index; serum levels must be monitored. Severe toxicity can occur at levels above 20 mcg/m L, including seizures, cardiac arrhythmias, and death. Use with caution as serious adverse effects may occur without warning.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, hypertension, cardiac arrhythmias, or seizure disorders. Monitor serum levels for toxicity. Risk of ventricular arrhythmias or seizures at high doses.
Monitor serum theophylline levels; adjust dose accordingly,Risk of toxicity is increased in patients with hepatic impairment, congestive heart failure, cor pulmonale, and elderly patients,May exacerbate or induce peptic ulcer disease, seizures, and other cardiac arrhythmias,Concurrent use with other xanthines can increase toxicity,Smoking cessation decreases clearance and may require dose reduction
Hypersensitivity to dyphylline or any xanthine derivative. Uncontrolled arrhythmias. Active seizure disorder. Severe hypotension. Concurrent use with other xanthines (e.g., theophylline).
Hypersensitivity to theophylline or any component,Active seizure disorder unless adequately controlled with medications,Severe cardiac arrhythmias (e.g., ventricular tachycardia),Pregnancy (controversial; use only if clearly needed)
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase adverse effects like nervousness and palpitations. No significant food interactions other than caffeine. Alcohol may increase CNS stimulation.
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. High-fat meals may slow absorption of extended-release formulations. No other significant food interactions.
Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are considered low. First trimester: No evidence of major malformations. Second and third trimesters: No known fetal harm, but high doses may cause transient neonatal tachycardia or irritability due to placental transfer. Avoid use near term if possible due to potential neonatal effects.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of fetal tachycardia, jitteriness, and hypoglycemia due to maternal theophylline levels; no clear teratogenic signal. Close monitoring recommended.
Dyphylline is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 0.7. Estimated infant dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants. However, monitor for signs of irritability or sleep disturbances.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability, jitteriness, and feeding intolerance have been reported. Caution advised; monitor infant for adverse effects. Benefit-risk assessment required.
Pregnancy may alter the pharmacokinetics of methylxanthines due to increased plasma volume and decreased protein binding. However, dyphylline is not extensively protein-bound, so changes may be minimal. No specific dose adjustment is recommended, but monitor clinical response and toxicity. Avoid doses exceeding standard recommendations.
Pregnancy increases theophylline clearance by 20-40% due to increased hepatic metabolism and renal blood flow. Monitor serum levels and adjust dose to maintain therapeutic range. Consider extended-release formulations for stable levels. Postpartum: clearance may decrease rapidly, requiring dose reduction.
Dyphylline (Lufyllin) is a xanthine bronchodilator that is not metabolized to theophylline, making it an alternative for patients who cannot tolerate theophylline. It is 2-3 times less potent than theophylline, requiring higher doses. Renal excretion is the primary elimination route; dose adjustment is needed in renal impairment. Monitor drug interactions with cimetidine, quinolones, and macrolides, though less severe than with theophylline. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Therapeutic levels are not well-defined, but target 6-18 mcg/m L for theophylline equivalents.
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Avoid use in patients with active peptic ulcer disease. Ethylenediamine component may cause allergic reactions in sensitive patients. Dose adjustment required in hepatic impairment, heart failure, or elderly. Tachyphylaxis may occur with prolonged use. Cigarette smoking increases clearance; monitor levels closely. Consider drug interactions with cimetidine, fluoroquinolones, and macrolides which decrease clearance.
Take this medication exactly as prescribed, do not double doses if missed.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report any signs of toxicity such as nausea, vomiting, insomnia, anxiety, or palpitations.,Do not crush or chew extended-release tablets unless instructed.,Maintain adequate hydration to help prevent side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver, kidney, or heart disease.
Do not chew or crush extended-release tablets; swallow whole.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, rapid heartbeat, or seizures immediately.,Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Inform your doctor if you have a history of seizures, ulcers, or liver disease.,Do not smoke or stop smoking without medical advice as it affects how this medication works.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUFYLLIN vs AMINOPHYLLINE DYE FREE, answered by our medical review team.
LUFYLLIN is a Xanthine Bronchodilator that works by LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.. AMINOPHYLLINE DYE FREE is a Xanthine Bronchodilator that works by Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUFYLLIN and AMINOPHYLLINE DYE FREE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUFYLLIN is: 200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.. The standard adult dose of AMINOPHYLLINE DYE FREE is: Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUFYLLIN and AMINOPHYLLINE DYE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUFYLLIN is classified as Category C. Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are . AMINOPHYLLINE DYE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.